A pharmaceutical composition which comprises a pharmaceutically acceptable carrier together with an in vivo fibrinolytic enzyme as defined herein wherein the catalytic site essential for fibrinolytic activity is blocked by a group which is removable by hydrolysis at a rate such that the pseudo-first order rate constant for hydrolysis is in the range 10.sup.-6 sec.sup.-1 to 10.sup.-3 sec.sup.-1 in isotonic aqueous media at pH 7.4 at 37.degree. C.; is useful in the treatment of venous thrombosis.
一种制药组合物,其包括一种在此定义下的体内纤溶酶和一种药用可接受载体,其中对于纤溶活性至关重要的催化位点被一种可通过
水解去除的基团所阻塞,其在等渗pH 7.4、37℃的
水溶介质中的伪一级速率常数在10.sup.-6秒.sup.-1至10.sup.-3秒.sup.-1范围内;适用于静脉血栓的治疗。